Jay N. Cohn, MD

Professor of Medicine, Cardiovascular Division

Jay N. Cohn

Contact Info

Mailing Address:
UMN – Cardiovascular Division
420 Delaware Street SE
MMC 508 Mayo
8508A (Campus Delivery Code)
Minneapolis, MN 55455

Administrative Assistant Name
Cheryl Tincher

Administrative Phone

Administrative Email

Administrative Fax Number

Professor of Medicine, Cardiovascular Division

Director, Rasmussen Center for Cardiovascular Disease Prevention


Medical School, Weill Cornell Medical College, New York, NY

Residency, Beth Israel Deaconess Medical Center, Boston, MA

Fellowship, Georgetown University Medical Center, Washington, DC


Jay N. Cohn, M.D., is Professor of Medicine and served as Director of the Cardiovascular Division from 1974-1996. He was instrumental in initiating the subspecialty of heart failure and founded the Heart Failure Society of America, of which he served as its first president, and the Journal of Cardiac Failure, which he served as its first Editor in Chief. His research has transitioned over the years from management of heart failure and severe cardiovascular diseases to an emphasis on early detection and preventive therapy through the Rasmussen Center for Cardiovascular Disease Prevention.

Awards & Recognition

Dr. Cohn has received recognition for his research and contributions from the American Heart Association, the American College of Cardiology, the American College of Physicians, the Heart Failure Society of America, the High Blood Pressure Research Council, and the Universities of Minnesota and Cornell

Professional Associations

  • Director, Rasmussen Center for Cardiovascular Disease Prevention
  • President, International Society of Cardiovascular Phamacotherapy (2008-2010)
  • Scientific Advisory Committee (1996-1998)
  • Victor Chang Cardiac Research Institute, Sydney, Australia (1997)
  • President, International Society of Hypertension (1996)



Selected Publications:

  • Cohn JN. Clinical trials: Heart failure treatment – clinical trials versus clinical practice. Nat Rev Cardiol 2016;13:316-8.
  • Cohn JN. Slowing the progression of cardiovascular disease. J Am Coll Cardiol 2016;67:1698- 700.
  • Cohn JN. Trials and tribulations. J Card Failure 2016;22:180-1
  • Florea VG, Cohn JN. Disease prevention in heart failure. In: Mann DL, Felker GM, Eds. Heart Failure: A Companion to Braunwald’s Heart Disease 3rd Ed. Elsevier, Pennsylvania. 2016; pp. 499-513.
  • Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, Clemenza F, Tognoni G, Anand IS, Cohn JN, Anker SD, Tavazzi L, Latini R on the behalf of GISSI-HF and Val-HeFT Investigators. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur J Heart Fail 2015;17:424-433.
  • Cohn JN. Prevention of cardiovascular disease. Trends Cardiovasc Med 2015;25:436-442.
  • Ling HZ, Flint J, Damgaard M, Bonfils PK, Cheng AS, Aggarwal S, Velmurugan S, Mendonca M, Rashid M, Kang S, Papalia F, Weissert S, Coats CJ, Thomas M, Kuskowski M, Cohn JN, Woldman S, Anand IS, Okonko DO. Calculated plasma volume status and prognosis in chronic heart failure. Eur J Heart Fail 2015;17:35-43.
  • McNamara DM, Taylor AL, Tam SW, Worcel M, Yancy CW, Hanley-Yanez K, Cohn JN, Feldman AM. G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT. JACC Heart Fail 2014;2:551-557.
  • Anand IS, Win S, Rector TS, Cohn JN, Taylor AL. Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: Results from the A-HeFT Trial. Circ Heart Fail 2014;7:759- 765.
  • Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res 2014;114:1815-1826.
  • Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail 2014;7:418-426.
  • Cohn JN. Heart failure in 2013: Continue what we are doing to treat HF, but do it better. Nat Rev Cardiol 2014;11:69-70.
  • Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Piña IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 2013;15:1082-1094.
  • Cohn JN. The message is clear: Prevent as well as treat acute myocardial infarction. Circulation 2013;128:2554-2556.
  • Francis GS, Cohn JN: Cardiac failure and the autonomic nervous system. In: Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. Eds: Mathias CJ, Bannister R. 5th Edition. Oxford University Press, 2013:761-769.



University of Minnesota Medical Center

Board Certifications

Internal Medicine

Clinical Interests

Heart failure; Prevention

Hospital Privileges

University of Minnesota Medical Center, Fairview